Prostaglandin E2 inhibits in-vitro mineral deposition by human periodontal ligament cells via modulating the expression of TWIST1 and RUNX2

Journal of Periodontal Research

Volumn 49, Issue 6, 2014, Pages 777-784

  Manokawinchoke, J ^a   Pimkhaokhum, A ^a   Everts, V ^b   Pavasant, P ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Human periodontal ligament cells; in vitro mineral deposition; PGE2; RUNX2; TWIST1

Indexed keywords

ALIZARIN RED S; ANTHRAQUINONE DERIVATIVE; COLORING AGENT; CYCLIC AMP DEPENDENT PROTEIN KINASE; NUCLEAR PROTEIN; OSTEOCALCIN; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E2; RUNX2 PROTEIN, HUMAN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR TWIST; TWIST1 PROTEIN, HUMAN;

AGONISTS; BONE DEVELOPMENT; CELL CULTURE; CELL DIFFERENTIATION; CULTURE TECHNIQUE; CYTOLOGY; DIAGNOSTIC USE; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HOMEOSTASIS; HUMAN; PERIODONTAL LIGAMENT; POLYMERASE CHAIN REACTION; PROCEDURES; UPREGULATION;

ANTHRAQUINONES; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELLS, CULTURED; COLORING AGENTS; CORE BINDING FACTOR ALPHA 1 SUBUNIT; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMANS; NUCLEAR PROTEINS; OSTEOCALCIN; OSTEOGENESIS; PERIODONTAL LIGAMENT; POLYMERASE CHAIN REACTION; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; RNA, SMALL INTERFERING; TWIST TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 84909944317     PISSN: 00223484     EISSN: 16000765     Source Type: Journal    
DOI: 10.1111/jre.12162     Document Type: Article

References (42)

1. Akaogi J, Nozaki T, Satoh M, Yamada H. Role of PGE2 and EP receptors in the pathogenesis of rheumatoid arthritis and as a novel therapeutic strategy. Endocr Metab Immune Disord Drug Targets 2006;6:383-394.
2. Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol 2012;188:21-28.
3. Aronoff DM, Canetti C, Peters-Golden M. Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. J Immunol 2004;173:559-565.
4. Huang S, Wettlaufer SH, Hogaboam C, Aronoff DM, Peters-Golden M. Prostaglandin E(2) inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoid 2 receptor and cAMP signaling. Am J Physiol Lung Cell Mol Physiol 2007;292:L405-L413.
5. Kolodsick JE, Peters-Golden M, Larios J, Toews GB, Thannickal VJ, Moore BB. Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am J Respir Cell Mol Biol 2003;29:537-544.
6. White ES, Atrasz RG, Dickie EG et al. Prostaglandin E(2) inhibits fibroblast migration by E-prostanoid 2 receptor-mediated increase in PTEN activity. Am J Respir Cell Mol Biol 2005;32:135-141.
7. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-342.
8. Coetzee M, Haag M, Kruger MC. Effects of arachidonic acid and docosahexaenoic acid on differentiation and mineralization of MC3T3-E1 osteoblast-like cells. Cell Biochem Funct 2009;27:3-11.
9. Hagino H, Kuraoka M, Kameyama Y, Okano T, Teshima R. Effect of a selective agonist for prostaglandin E receptor subtype EP4 (ONO-4819) on the cortical bone response to mechanical loading. Bone 2005;36:444-453.
10. Minamizaki T, Yoshiko Y, Kozai K, Aubin JE, Maeda N. EP2 and EP4 receptors differentially mediate MAPK pathways underlying anabolic actions of prostaglandin E2 on bone formation in rat calvaria cell cultures. Bone 2009;44:1177-1185.
11. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001;41:661-690.
12. Alander CB, Raisz LG. Effects of selective prostaglandins E2 receptor agonists on cultured calvarial murine osteoblastic cells. Prostaglandins Other Lipid Mediat 2006;81:178-183.
13. Paralkar VM, Borovecki F, Ke HZ et al. An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc Natl Acad Sci U S A 2003;100:6736-6740.
14. Weinreb M, Shamir D, Machwate M, Rodan GA, Harada S, Keila S. Prostaglandin E2 (PGE2) increases the number of rat bone marrow osteogenic stromal cells (BMSC) via binding the EP4 receptor, activating sphingosine kinase and inhibiting caspase activity. Prostaglandins Leukot Essent Fatty Acids 2006;75:81-90.
15. Raisz LG, Woodiel FN. Effects of selective prostaglandin EP2 and EP4 receptor agonists on bone resorption and formation in fetal rat organ cultures. Prostaglandins Other Lipid Mediat 2003;71:287-292.
16. Zhang J, Wang JH. BMP-2 mediates PGE(2) -induced reduction of proliferation and osteogenic differentiation of human tendon stem cells. J Orthop Res 2012;30:47-52.
17. Keila S, Kelner A, Weinreb M. Systemic prostaglandin E2 increases cancellous bone formation and mass in aging rats and stimulates their bone marrow osteogenic capacity in vivo and in vitro. J Endocrinol 2001;168:131-139.
18. Ke HZ, Crawford DT, Qi H et al. A nonprostanoid EP4 receptor selective prostaglandin E2 agonist restores bone mass and strength in aged, ovariectomized rats. J Bone Miner Res 2006;21:565-575.
19. Li M, Thompson DD, Paralkar VM. Prostaglandin E(2) receptors in bone formation. Int Orthop 2007;31:767-772.
20. Tanaka M, Sakai A, Uchida S et al. Prostaglandin E2 receptor (EP4) selective agonist (ONO-4819.CD) accelerates bone repair of femoral cortex after drill-hole injury associated with local upregulation of bone turnover in mature rats. Bone 2004;34:940-948.
21. Yoshida K, Oida H, Kobayashi T et al. Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. Proc Natl Acad Sci U S A 2002;99:4580-4585.
22. Komori T, Yagi H, Nomura S et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997;89:755-764.
23. Otto F, Thornell AP, Crompton T et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997;89:765-771.
24. Bialek P, Kern B, Yang X et al. A twist code determines the onset of osteoblast differentiation. Dev Cell 2004;6:423-435.
25. Yousfi M, Lasmoles F, Marie PJ. TWIST inactivation reduces CBFA1/RUNX2 expression and DNA binding to the osteocalcin promoter in osteoblasts. Biochem Biophys Res Commun 2002;297:641-644.
26. el Ghouzzi V, Le Merrer M, Perrin-Schmitt F et al. Mutations of the TWIST gene in the Saethre-Chotzen syndrome. Nat Genet 1997;15:42-46.
27. Howard TD, Paznekas WA, Green ED et al. Mutations in TWIST, a basic helix-loop-helix transcription factor, in Saethre-Chotzen syndrome. Nat Genet 1997;15:36-41.
28. Yousfi M, Lasmoles F, Lomri A, Delannoy P, Marie PJ. Increased bone formation and decreased osteocalcin expression induced by reduced Twist dosage in Saethre-Chotzen syndrome. J Clin Investig 2001;107:1153-1161.
29. Miraoui H, Severe N, Vaudin P, Pages JC, Marie PJ. Molecular silencing of Twist1 enhances osteogenic differentiation of murine mesenchymal stem cells: implication of FGFR2 signaling. J Cell Biochem 2010;110:1147-1154.
30. Lee MS, Lowe GN, Strong DD, Wergedal JE, Glackin CA. TWIST, a basic helix-loop-helix transcription factor, can regulate the human osteogenic lineage. J Cell Biochem 1999;75:566-577.
31. Danciu TE, Li Y, Koh A, Xiao G, McCauley LK, Franceschi RT. The basic helix loop helix transcription factor Twist1 is a novel regulator of ATF4 in osteoblasts. J Cell Biochem 2012;113:70-79.
32. Luckprom P, Wongkhantee S, Yongchaitrakul T, Pavasant P. Adenosine triphosphate stimulates RANKL expression through P2Y1 receptor-cyclo-oxygenase-dependent pathway in human periodontal ligament cells. J Periodontal Res 2010;45:404-411.
33. Wongkhantee S, Yongchaitrakul T, Pavasant P. Mechanical stress induces osteopontin expression in human periodontal ligament cells through rho kinase. J Periodontol 2007;78:1113-1119.
34. Kanzaki H, Chiba M, Shimizu Y, Mitani H. Periodontal ligament cells under mechanical stress induce osteoclastogenesis by receptor activator of nuclear factor kappaB ligand up-regulation via prostaglandin E2 synthesis. J Bone Miner Res 2002;17:210-220.
35. Sooampon S, Manokawinchoke J, Pavasant P. Transient receptor potential vanilloid-1 regulates osteoprotegerin/RANKL homeostasis in human periodontal ligament cells. J Periodontal Res 2013;48:22-29.
36. Kambe T, Maruyama T, Nakai Y et al. Discovery of novel prostaglandin analogs as potent and selective EP2/EP4 dual agonists. Bioorg Med Chem 2012;20:2235-2251.
37. Sakuma Y, Tanaka K, Suda M et al. Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide. J Bone Miner Res 2000;15:218-227.
38. Suzawa T, Miyaura C, Inada M et al. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 2000;141:1554-1559.
39. Weinreb M, Grosskopf A, Shir N. The anabolic effect of PGE2 in rat bone marrow cultures is mediated via the EP4 receptor subtype. Am J Physiol 1999;276:E376-E383.
40. Li X, Okada Y, Pilbeam CC et al. Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro. Endocrinology 2000;141:2054-2061.
41. Serra-Pages M, Olivera A, Torres R, Picado C, de Mora F, Rivera J. E-prostanoid 2 receptors dampen mast cell degranulation via cAMP/PKA-mediated suppression of IgE-dependent signaling. J Leukoc Biol 2012;92:1155-1165.
42. Srivastava V, Dey I, Leung P, Chadee K. Prostaglandin E2 modulates IL-8 expression through formation of a multiprotein enhanceosome in human colonic epithelial cells. Eur J Immunol 2012;42:912-923.